GenKyoTex Stock

GenKyoTex EV/EBIT

Delisted·Oct 5, 2021

The EV/EBIT (Enterprise Value to EBIT) of GenKyoTex (GKTX.PA) as of Aug 15, 2026 is -3.35. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -6.08 — a change of -44.89% (higher).

EV/EBIT

-3.35

YoY

-44.89%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of GenKyoTex is 2026 -3.35 . EV/EBIT (Enterprise Value to EBIT) of GenKyoTex was 2025 -6.08 . It decreases by -44.89% higher compared to the previous year.

The GenKyoTex EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2017
-9.19 base
Jan 1, 2018
-7.93 base
Jan 1, 2019
-2.66 base
Jan 1, 2020
-3.15 base
Jan 1, 2021 (e)
0.00 base
Jan 1, 2022 (e)
0.00 base
Jan 1, 2023 (e)
0.00 base
Jan 1, 2024 (e)
0.00 base
YEARPRICE-TO-EBIT
2024 est -
2023 est -
2022 est -
2021 est -
2020 -3.15
2019 -2.66
2018 -7.93
2017 -9.19
2016 -33.55
2015 -4.12
2014 -3.71
2013 -
2012 -
2011 -
Access this data via the Eulerpool API

GenKyoTex Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides GenKyoTex's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates GenKyoTex's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots GenKyoTex's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if GenKyoTex grows earnings faster than its peers.

GenKyoTex Stock analysis

What does GenKyoTex do? GenKyoTex SA is a Swiss biotechnology company specializing in the development of innovative therapies for the treatment of inflammatory diseases. The company was founded in 2006 by Dr. Elias Papatheodorou and Dr. Takashi Mizuno and is headquartered near Lausanne. The history of GenKyoTex SA began with the discovery of a new enzyme called NOX (NADPH oxidase) 1/4, which plays a crucial role in the onset of inflammation. This was the starting point for the development of inhibitors that reduce NOX activity and thus halt the progression of inflammatory diseases such as fibrosis, arthritis, or kidney failure. GenKyoTex SA's business model is based on the development and marketing of therapeutics based on NOX inhibitor technology. The company works closely with leading experts and research institutions to develop innovative drugs and conduct clinical trials. The different divisions of GenKyoTex SA include expertise in formulation, manufacturing, and stabilization of active ingredients and drugs, as well as the development of clinical trials and optimization of production processes. The company has its own research and development department, allowing it to oversee the entire value chain associated with its products. The company has developed a range of products based on NOX inhibitor technology. One of these is GKT831, a drug used to treat patients with idiopathic pulmonary fibrosis (IPF). IPF is a chronic and progressive condition in which lung tissue becomes inflamed and scarred, impairing oxygen uptake. GKT831 has shown promising results in a clinical program. Another product from GenKyoTex SA is GKT771, a drug used to treat patients with diabetic nephropathy. Diabetic nephropathy is a complication of diabetes in which kidney function deteriorates. GKT771 has shown positive results in a phase 2 study and is now in phase 3 development. Overall, GenKyoTex SA is an innovative company focused on the development of drugs for the treatment of inflammation. The company has expertise in NOX inhibitor technology and has already brought several promising products to market or in development. Thanks to collaboration with leading experts and research institutions, GenKyoTex SA can accelerate the development of new drugs and improve patients' quality of life. GenKyoTex is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GenKyoTex stock

EV/EBIT (Enterprise Value to EBIT) of GenKyoTex is -3.35 in 2026.

EV/EBIT (Enterprise Value to EBIT) of GenKyoTex changed from -6.08 to -3.35, representing a -44.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) GenKyoTex since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s GenKyoTex with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — GenKyoTex

All Key Metrics — GenKyoTex